S1764
补体血清 人
lyophilized powder
别名:
人血清补充剂
登录 查看组织和合同定价。
选择尺寸
关于此项目
Biological source:
human
Origin:
USA origin
Form:
lyophilized powder
Shipped in:
dry ice
产品名称
补体血清 人, lyophilized powder
biological source
human
form
lyophilized powder
origin
USA origin
technique(s)
cell culture | mammalian: suitable
impurities
virus, tested
shipped in
dry ice
storage temp.
−20°C
Quality Level
Analysis Note
溶血滴度（CH50单位/ml）通过Kabat/Mayer法测定。实际滴度见标签。
Application
人补体血清已用于：
- 培养DLD-1或SW-620细胞，以量化C5a释放
- 多重头抗体C3d结合试验
- 补体依赖性细胞毒性试验
人补体血清已用于：
- 培养DLD-1或SW-620细胞，以量化C5a释放
- 多重头抗体C3d结合试验
- 补体依赖性细胞毒性试验
补体血清的活性可通过体外溶血试验测定。
Disclaimer
仅供研究使用。本品在法国的科研应用受到监管，包括用于进口和出口活动（法国《公共卫生法典》Public Health Code Article L 1211-1 paragraph 2）。如《公共卫生法典》所述，购买者（即最终用户）需要从法国研究部(France Ministry of Research)获得进口授权。订购此产品即代表您已确认获得合法的进口授权。
General description
补体血清从混合的人血浆中制备，并根据标签上指示的血清量进行冻干。
Physical form
由标签所示含量血清制成的冻干粉末
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
高风险级别生物产品--人源产品
此项目有
Yui Suzuki et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 25(14), 4388-4399 (2019-04-26)
The anti-CCR4 mAb, mogamulizumab, offers therapeutic benefit to patients with adult T-cell leukemia-lymphoma (ATL), but skin-related adverse events (AE) such as erythema multiforme occur frequently. The purpose of this study was to determine the mechanisms by which mogamulizumab causes skin-related
Savannah E Butler et al.
Frontiers in immunology, 11, 618685-618685 (2021-02-16)
Understanding humoral immune responses to SARS-CoV-2 infection will play a critical role in the development of vaccines and antibody-based interventions. We report systemic and mucosal antibody responses in convalescent individuals who experienced varying severity of disease. Whereas assessment of neutralization
Anaïs Thiriard et al.
Frontiers in immunology, 14, 1107156-1107156 (2023-04-04)
To comprehensively analyze the quality of the antibody response between children with Multisystem inflammatory syndrome (MIS-C) and age-matched controls at one month after SARS-CoV-2 exposure, and infected in the same time-period. Serum from 20 MIS-C children at admission, and 14
S Nowicki et al.
Infection and immunity, 63(12), 4790-4794 (1995-12-01)
Human C1q displayed a dose-dependent protection of gonococcal cells (GC) from the bactericidal effect of newborn rat serum. All rat pups injected with C1q-preincubated GC developed bacteremia, while none of the animals injected with GC only were infected. After clearance
Lisa Tomasi et al.
Open forum infectious diseases, 9(11), ofac554-ofac554 (2022-12-06)
The basis of the less severe clinical presentation of coronavirus disease 2019 (COVID-19) in children as compared with adults remains incompletely understood. Studies have suggested that a more potent boosting of immunity to endemic common cold coronaviruses (HCoVs) may protect
相关内容
Datasheet
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持